Attovia Therapeutics, Inc. (ATTO) — real insider trading activity disclosed to the SEC, tracked automatically as new Form 4 filings are reported. Most recent: WALSH COLIN — 2 open-market purchases between 2026-08-05 and 2026-08-06, totaling $10,285,000.
Transactions disclosed by company insiders to the SEC on Form 4, most recent first.
| Insider | Role | Date | Shares | Value |
|---|---|---|---|---|
| Redmile Group, LLC | Insider | 2026-08-06 | 782,854 | $0 |
| Redmile Group, LLC | Insider | 2026-08-06 | 200,000 | $3,400,000 |
| Redmile Group, LLC | Insider | 2026-08-06 | 400,000 | $6,800,000 |
| Sanofi | Insider | 2026-08-06 | 782,855 | $0 |
| Sanofi | Insider | 2026-08-06 | 300,000 | $5,100,000 |
| GOLDMAN SACHS GROUP INC | Insider | 2026-08-06 | 1,957,134 | $0 |
| GOLDMAN SACHS GROUP INC | Insider | 2026-08-06 | 478,498 | $0 |
| GOLDMAN SACHS GROUP INC | Insider | 2026-08-06 | 500,000 | $8,500,000 |
| WALSH COLIN | Director | 2026-08-06 | 1,957,134 | $0 |
| WALSH COLIN | Director | 2026-08-06 | 478,498 | $0 |
Data compiled from public SEC filings. This is informational reporting, not investment advice.
A new Form 4 filing shows Colin Walsh, a director at Attovia Therapeutics, Inc. (ATTO), purchased 500,000 shares of company stock on the open market on August 6, 2026. The purchase price was $17.00 per share, bringing the total outlay to $8,500,000.00. Following the transaction, Walsh’s indirect holdings — held via a trust or entity … Read more
Goldman Sachs Group Inc. disclosed the purchase of 500,000 shares of Attovia Therapeutics, Inc. (ATTO) on the open market on August 6, 2026, according to a Form 4 filed with the SEC. The shares were bought at $17.00 apiece for a total outlay of $8,500,000. Following the transaction, Goldman Sachs holds 3,020,632 shares indirectly, through … Read more
Attovia Therapeutics, Inc. (ATTO) has another notable name on its insider buying ledger. venBio Global Strategic Fund IV, L.P., listed as an insider of the company, purchased 382,352 shares on the open market on August 6, 2026, at a price of $17.00 per share. The transaction totaled $6,499,984.00, funded directly by the fund rather than … Read more
Sanofi has disclosed a substantial open-market purchase of shares in Attovia Therapeutics, Inc. (ATTO), according to a Form 4 filed with the SEC. The filing shows Sanofi bought 300,000 shares on August 6, 2026 at a price of $17.00 per share, a transaction valued at $5,100,000.00. Following the purchase, Sanofi’s stake in Attovia stands at … Read more
Attovia Therapeutics, Inc. (NASDAQ: ATTO) is showing a fresh cluster of insider buying, with Redmile Group, LLC — a 10%+ owner of the company — disclosing an open-market purchase of 200,000 shares at $17.00 per share on August 6, 2026. The transaction, filed on Form 4, totaled $3,400,000 and brings Redmile Group’s directly held stake … Read more
Frazier Life Sciences XI, L.P., an insider at Attovia Therapeutics, Inc. (ATTO), disclosed an open-market purchase of 588,235 shares on August 6, 2026, according to a Form 4 filed with the SEC. The shares were bought at $17.00 apiece, for a total outlay of $9,999,995.00 — a purchase sized almost exactly to the $10 million … Read more